William Gradishar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3722995/publications.pdf

Version: 2024-02-01

27 448 10
papers citations h-index

10 21 h-index g-index

28 28 all docs citations

28 times ranked 929 citing authors

#	Article	IF	CITATIONS
1	Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer. Molecular Cancer Therapeutics, 2017, 16, 1412-1420.	4.1	114
2	Association of <i>BRCA1</i> Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk. Journal of Adolescent and Young Adult Oncology, 2016, 5, 337-343.	1.3	53
3	Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). Journal of the National Cancer Institute, 2015, 107, .	6.3	52
4	Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. Oncologist, 2017, 22, 797-803.	3.7	40
5	Targeted eHealth Intervention to Reduce Breast Cancer Survivors' Fear of Recurrence: Results From the FoRtitude Randomized Trial. Journal of the National Cancer Institute, 2021, 113, 1495-1505.	6.3	32
6	The National Physicians Cooperative: transforming fertility management in the cancer setting and beyond. Future Oncology, 2018, 14, 3059-3072.	2.4	30
7	Feasibility and acceptability of intensive longitudinal data collection of activity and patient-reported outcomes during chemotherapy for breast cancer. Quality of Life Research, 2019, 28, 3333-3346.	3.1	19
8	Oncologists' Role in Patient Fertility Care. JAMA Oncology, 2016, 2, 171.	7.1	18
9	Landmark trials in endocrine adjuvant therapy for breast carcinoma. Cancer, 2006, 106, 975-981.	4.1	16
10	Daily Physical Activity and Symptom Reporting in Breast Cancer Patients Undergoing Chemotherapy: An Intensive Longitudinal Examination. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2608-2616.	2.5	12
11	Are Biosimilars the Future of Oncology and Haematology?. Drugs, 2019, 79, 1609-1624.	10.9	10
12	Management of advanced breast cancer with the epothilone B analog, ixabepilone. Drug Design, Development and Therapy, 2009, 3, 163.	4.3	9
13	Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience. JCO Precision Oncology, 2022, , .	3.0	9
14	Social cognitive variables and physical activity during chemotherapy for breast cancer: An intensive longitudinal examination. Psycho-Oncology, 2022, 31, 425-435.	2.3	8
15	Fulvestrant in the treatment of postmenopausal women with advanced breast cancer. Expert Review of Anticancer Therapy, 2005, 5, 445-453.	2.4	6
16	Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management. Endocrinology, 2022, 163, .	2.8	5
17	Innovating Cancer Care Delivery: the Example of the 4R Oncology Model for Colorectal Cancer Patients. Current Treatment Options in Oncology, 2019, 20, 11.	3.0	3
18	A Technology-Based Physical Activity Intervention for Patients With Metastatic Breast Cancer (Fit2ThriveMB): Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e24254.	1.0	3

#	Article	IF	CITATIONS
19	Study design and protocol for tailored Acceptance and Commitment Therapy (ACT) to optimize quality of life in women living with metastatic breast cancer. Contemporary Clinical Trials Communications, 2022, 25, 100870.	1.1	3
20	Evaluation of the Novel 4R Oncology Care Planning Model in Breast Cancer: Impact on Patient Self-Management and Care Delivery in Safety-Net and Non–Safety-Net Centers. JCO Oncology Practice, 2021, 17, e1202-e1214.	2.9	2
21	Using ecological momentary assessment to understand associations between daily physical activity and symptoms in breast cancer patients undergoing chemotherapy. Supportive Care in Cancer, 2022, 30, 6613-6622.	2.2	2
22	Addressing Fertility: an Essential Aspect of Comprehensive Care for Young Patients with Breast Cancer. Current Breast Cancer Reports, 2020, 12, 381-390.	1.0	1
23	Reply to S. Sorscher. Journal of Clinical Oncology, 2021, 39, 1188-1189.	1.6	1
24	In Reply. Oncologist, 2017, 22, 1540-1540.	3.7	0
25	Abstract P2-02-05: Dynamic circulating tumor cell changes in enumeration and HER2 expression during systemic therapy for metastatic breast cancer. Cancer Research, 2022, 82, P2-02-05-P2-02-05.	0.9	O
26	Abstract P2-01-04: Esr1 hotspot mutations in circulating tumor DNA mutation are associated with endocrine therapy resistance in metastatic breast cancer. Cancer Research, 2022, 82, P2-01-04-P2-01-04.	0.9	0
27	Abstract P2-01-08: <i>Esr1</i> Y537 mutations are associated with increased baseline circulating tumor cells enumeration for patients with estrogen receptor positive metastatic breast cancer. Cancer Research, 2022, 82, P2-01-08-P2-01-08.	0.9	0